Huang et al. (2019) showed that CAFs promote angiogenesis of hepatocellular carcinoma via the vascular endothelial growth factor-mediated EZH2/vasohibin 1 pathway and may be a potentially useful therapeutic target for hepatocellular carcinoma. This evidence concerns the gene EZH2 and hepatocellular carcinoma.